← All problems

Problem

De novo design of protein binders to a given target

Given a target protein (ideally a specified epitope), generate novel protein sequences - mini-binders, nanobodies/VHHs or full antibodies - that bind it tightly and specifically, without starting from a known binder. This is the core technical step in making biologic drugs designable rather than discovered, which is why it attracts both large pharma partnerships and >$1B of venture funding. A design campaign counts as SOLVED for a target when a computational pipeline, run zero-shot on a defined epitope, yields wet-lab-confirmed binders at a double-digit hit rate with affinities in the low-nanomolar to picomolar range, reproducibly across a benchmark set of diverse and hard targets (membrane proteins, multimers, conformational epitopes). Current best published evidence: 16% zero-shot de novo antibody hit rate (Chai-2, 2025), 17-82% nanomolar hit rates on 6 of 7 BenchBB-style targets (PXDesign, 2025), and community competitions at 14% (Adaptyv EGFR round 2, Dec 2024). Field-wide, hit rates still span roughly 0.1-39% depending on target and assay, and hard targets/epitopes often yield nothing.

Funding

$2.92B

Raised by the 5 companies working on it.

Prize money for solving it$0
Open competition pools$0

Why it is still open

As of 2026 the problem is target-dependent, not solved: published hit rates range from ~0.1% to ~39% with no agreed definition, methods offer limited control over the binding site, and hard targets and hard epitopes often fail outright. Adaptyv's own analysis of its competition concluded expression is essentially solved and lead optimization works well, but nobody can predict computationally which designs will bind before wet-lab testing - so campaigns remain empirical.

Source: sciencedirect.com

Who is working on it

Chai Discovery$630M Chai-2, a zero-shot generative model reported at a 16% experimental hit rate for fully de novo antibody design against a defined epitope, plus the open Chai-1 structure model. InvestorsThrive Capital, OpenAI, Dimension, Menlo Ventures (incl. Anthology Fund with Anthropic), Oak HC/FT, General Catalyst, Index Ventures, Kleiner Perkins
Latent Labs$50M Latent-X, a no-code web platform that generates mini-binders and macrocycles from a target structure and epitope, with wet-lab-reported affinities from low micromolar (macrocycles) to picomolar (mini-binders). InvestorsRadical Ventures, Sofinnova Partners, 8VC, Kindred Capital, Pillar VC, Flying Fish, Isomer Capital, Jeff Dean (angel)
Nabla Bio$37M JAM (Joint Atomic Modeling) generative system for de novo antibody design; reported hundreds of functional VHH designs against GPCR targets CXCR4/CXCR7 with picomolar to low-nanomolar affinities. InvestorsRadical Ventures, Takeda
Generate:Biomedicines$1.20B Generative protein design platform (Chroma lineage) used to design antibodies and other protein therapeutics; lead clinical asset GB-0895 is an AI-designed anti-TSLP antibody. InvestorsFlagship Pioneering, Amgen, Novartis
Xaira Therapeutics$1.00B Launched out of the Baker lab lineage with de novo biologics design as its founding technical program, pairing generative design models with in-house large-scale data generation. InvestorsARCH Venture Partners, Foresite Capital, F-Prime Capital, NEA, Sequoia Capital, Lux Capital, Lightspeed Venture Partners, Parker Institute for Cancer Immunotherapy

Also active

EvolutionaryScale (now part of Biohub) ESM3 open-weights generative protein model, widely used as the sequence/structure backbone for third-party binder-design pipelines; team acquired by Chan Zuckerberg Biohub in Nov 2025. InvestorsNat Friedman & Daniel Gross (NFDG), Lux Capital, Amazon, NVentures (NVIDIA), Chan Zuckerberg Initiative / Biohub
Adaptyv Bio Runs the wet-lab validation layer for the field: express-and-measure service plus the public EGFR/Nipah design competitions and the BenchBB benchmark that define community hit-rate numbers.
Converge Bio Sells a generative-AI biologics toolkit to pharma and biotech customers, running design programs (including binder/antibody design) on their molecular data rather than owning a pipeline. InvestorsBessemer Venture Partners, TLV Partners, Vintage Investment Partners, Saras Capital

Funding for these is not counted: the problem is a small part of what they do, or they contribute data and tools.

Prizes

What counts as solved

The acceptance condition, stated in Lean 4. Measurements a computer cannot produce on its own are named inputs, supplied by whoever attests them.

import Mathlib

/-!
# De novo design of protein binders to a given target

Modelled on the Adaptyv Bio protein-design competitions (rounds against EGFR and
similar published targets): a team submits a small, capped number of designed
sequences against a disclosed, publicly studied target protein; the organiser expresses
them and measures binding in a standard biophysical assay. Scoring is a wet-lab hit
rate plus best measured affinity, with a novelty guard so that rediscovering a known
binder does not count.

Concrete in Lean: the capped submission list, the per-design pass predicate, the hit
rate as a ratio over the expressed designs, and the acceptance Prop with rungs.

Opaque oracle (`Assay`): everything measured. Expression/solubility, dissociation
constant K_D from SPR/BLI against the disclosed target, an off-target control, and the
sequence-novelty call against the training/known-binder set. Attesters: the contract lab
running the pinned assay protocol plus the organiser holding the novelty reference set.
Nothing here is a biological or safety claim; the board's scope is a named benchmark
target and the lab's own protocol and compliance review govern what may be ordered.

Units: K_D in nanomolar (nM); identity as a fraction in [0, 1]; hit rate dimensionless.
-/

namespace OpenSpur.Problems.DeNovoBinderDesign

structure Design where
  sequence : String

/-- Wet-lab and novelty results for one design (oracle). -/
structure Assay where
  expressed : Design → Prop          -- soluble expression at the pinned scale
  kd : Design → ℝ                    -- nM against the disclosed benchmark target
  offTargetKd : Design → ℝ           -- nM against the pinned control protein
  maxIdentityToKnown : Design → ℝ    -- fraction identity to nearest known binder

structure Thresholds where
  maxDesigns : ℕ        -- submission cap, e.g. 10
  maxKd : ℝ             -- nM, e.g. 100
  minSelectivity : ℝ    -- off-target K_D / on-target K_D, e.g. 100
  maxIdentity : ℝ       -- novelty guard, e.g. 0.4
  minHitRate : ℝ        -- e.g. 0.2 of expressed designs

/-- A design counts as a hit: expressed, tight enough, selective, and novel. -/
def Hit (A : Assay) (T : Thresholds) (d : Design) : Prop :=
  A.expressed d ∧ 0 < A.kd d ∧ A.kd d ≤ T.maxKd ∧
  T.minSelectivity * A.kd d ≤ A.offTargetKd d ∧
  A.maxIdentityToKnown d ≤ T.maxIdentity

noncomputable section

def expressedCount (A : Assay) (ds : List Design) [DecidablePred A.expressed] : ℝ :=
  ((ds.filter fun d => decide (A.expressed d)).length : ℝ)

def hitCount (A : Assay) (T : Thresholds) (ds : List Design)
    [DecidablePred (Hit A T)] : ℝ :=
  ((ds.filter fun d => decide (Hit A T d)).length : ℝ)

/-- SOLVED: within the cap, the hit rate among expressed designs meets the bar. -/
def Solved (A : Assay) (T : Thresholds) (ds : List Design)
    [DecidablePred A.expressed] [DecidablePred (Hit A T)] : Prop :=
  ds.length ≤ T.maxDesigns ∧
  0 < expressedCount A ds ∧
  T.minHitRate * expressedCount A ds ≤ hitCount A T ds

def rung (T : Thresholds) (k : ℕ) : Thresholds :=
  { T with maxKd := T.maxKd / ((k : ℝ) + 1) }

end

/-- Tightening only the affinity bar keeps the hit set inside the looser bar. -/
theorem hit_mono (A : Assay) (T : Thresholds) (d : Design) (c : ℝ)
    (hc : c ≤ T.maxKd) (h : Hit A { T with maxKd := c } d) : Hit A T d := by
  obtain ⟨h1, h2, h3, h4, h5⟩ := h
  exact ⟨h1, h2, le_trans h3 hc, h4, h5⟩

end OpenSpur.Problems.DeNovoBinderDesign

Public resources

Join

Tell us what you want settled.

Two questions. We read every one.

I am a

What are you looking to solve?

Where should we reply?

Received

That is with us.

We read every message and reply to the ones we can help.